This analysis of the C-CAT database suggests that the ERBB2 R678Q mutation, present in approximately 1% of gastric cancer cases, is associated with a significantly reduced response to oxaliplatin-based therapy. This evidence concerns the gene ERBB2 and gastric cancer.